Navigation Links
Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International
Date:2/13/2009

Stemedica Cell Technologies, Inc., a leader in adult stem cell development, today announces that it has appointed Riccardo Nisato, MBA, PhD, as Director of Manufacturing and Clinical Business Development of Stemedica International, CH. Dr. Nisato will be responsible for replicating Stemedica's U.S. based operations to Stemedica's International's center based in Lausanne, Switzerland.

San Diego, Calif. (PRWEB) February 13, 2009 -- Stemedica Cell Technologies, Inc., a leader in adult stem cell development, today announces that it has appointed Riccardo Nisato, MBA, PhD, as Director of Manufacturing and Clinical Business Development of Stemedica International, CH. Dr. Nisato will be responsible for replicating Stemedica's U.S. based operations to Stemedica's International's center based in Lausanne, Switzerland.



A respected biologist, project leader and business consultant in the medical technology field, Dr. Nisato's specialty is the development of strategic options for cell therapy manufacturing that complies with Swiss Medic standards for Good Manufacturing Practice (GMP) in Switzerland. Dr. Nisato has a Master in Pharmacology from the University Paris V, a Ph.D. in Biology from the University of Geneva and an MBA in the Management of Technology from École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.

"We are delighted to add Dr. Nisato to our Stemedica International team. Our plans to serve Clinical Research Centers outside the United States with in-depth stem cell research, product development, manufacturing and Master Bank product capabilities will be significantly advanced by Dr. Nisato's leadership and experience. His expertise in the cell manufacturing processes, including his intimate interaction with researchers and clinicians involved in Phase I, Phase II studies and approved treatments derived from fetal and adult cells, combined with his years of consulting for medical technology companies will provide invaluable direction for our international development strategy," said Roger Howe, Chairman and CFO at Stemedica.

"The prospect that Stemedica International represents for establishing regulatory-approved clinical trials at high-accredited treatment facilities around the world, leading to successful treatment for patients with debilitating conditions, is an invigorating opportunity for me at this point in my career. I have been fortunate to extensively collaborate with researchers and surgeons involved in cell-based clinical trials and approved therapies for skin burn treatments for children and adults, so I am intimately aware of the difference that Stemedica International will make in the future. It's an honor to be in at ground level, working to build Stemedica into a worldwide leader in the adult stem cell industry," said Dr. Nisato.

Dr. Nisato will report to Dr. Alex Kharazi, Vice President, Research & Manufacturing for Stemedica International's partner organization, Stemedica Cell Technologies and to Dr. Nikolai Tankovich, Chairman of Stemedica International and President and Medical Officer of Stemedica Cell Technologies.

"Dr. Nisato has the perfect combination of medical knowledge in pharmacology and cell biology as well as with medically-oriented business development that makes him the perfect choice for this significant new role. We are very fortunate to have attracted his interest and to have brought about this significant appointment. I am excited about extending our solid U.S. work to Europe under Dr. Nisato's strategic oversight," said Dr. Tankovich.

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is headquartered in San Diego, California.

From more information regarding Stemedica Cell Technologies, Inc. or the Dr Nisato appointment, contact Dave McGuigan at dmcguigan (at) stemedica (dot) com.

# # #

Read the full story at http://www.prweb.com/releases/stemedica-international/dr-nisato/prweb2036044.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Dr Nabil Dib Takes on Special Advisor Role to the Stemedica Board of Directors
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International
(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... assistance and financial planning services to communities in east Texas, is launching a ... Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: